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The global cardiovascular disease pandemic, current status 
and future projections
Despite encouraging advances in our knowledge of the 
prevention, diagnosis and treatment of atherothrombosis, 
cardiovascular disease (CVD) remains a major cause of disability 
and premature death throughout the world [1]. Globally an 
estimated 16.7 million deaths in the year 2010 were attributed 
to CVD; with projections showing a staggering 23.3 million 
by 2030. CVD mortality rates are considered equivalent to the 
combined number of deaths due to nutritional deficiencies, 
infectious diseases, and maternal and perinatal conditions [2]. 
This massive growth of CVD during the last decade is mainly due 
to the increasing incidence in low-and middle-income countries 
(LMICs) [2]. In 2012, the Developed and Caucasus and Central 
Asia regions had the highest CVD death rates in the world (>400 
deaths per 100,000 population, in both genders). Lowest CVD 
death rates were estimated for the Oceania region (85 deaths per 
100,000 population, in both genders) [3] (Fig. 1).
CVDs (including coronary heart disease (CHD), stroke and 
other CVD) cause more than 4 million deaths each year in the 
53 countries of the World Health Organization (WHO) European 
Region and over 1.9 million deaths in the European Union 
(EU) countries [4]. Data from the Organisation for Economic 
Co-operation and Development (OECD) show that in 2010, 
coronary heart disease (CHD) alone was responsible for 13% of 
all deaths in EU member states. However, mortality from CHD 
varies considerably being generally higher in the countries of the 
former communist bloc. Rates are also relatively high in Finland 
and Malta, being several times higher than in France, Portugal, 
the Netherlands and Spain. Rates are generally lower in the 
southern countries, frequently considered to be a consequence 
of the Mediterranean diet. In all countries, death rates for CHD 
are higher for men than women in 2012 [4] (Fig. 2).
Since the mid-1990s, CHD mortality rates have declined 
in most European countries. Declining tobacco consumption 
contributed significantly to reducing mortality rates but 
improvements in medical care have also played a part. A recent 
study compared short-term outcomes in patients with acute 
myocardial infarction (MI) in the United Kingdom (UK) and 
Sweden. Unadjusted 30-day mortality was more than a third 
higher in the UK (10.5% [95% CI: 10.4–10.6]) than in Sweden 
(7.6% [95% CI: 7.4–7.7]) in 2004–2010. The authors suggest that 
the difference is mostly due to the more rapid adoption of new 
technologies and recommendations for practice in Sweden than 
in the UK despite similar spending on acute MI in both countries 
[5]. In the United States of America (USA), CHD alone caused 
375,295 deaths. Each year an estimated 635,000 Americans have 
a new coronary attack (defined as first hospitalized MI or CHD 
death) [6].
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A B S T R A C T
Despite encouraging advances in prevention and treatment of atherothrombosis, cardiovascular 
disease (CVD) remains a major cause of deaths and disability worldwide and will continue to grow 
mainly due to the increase in incidence in low and middle income countries (LMIC). In Europe and the 
United States of America (USA), coronary heart disease (CHD) mortality rates have decreased since the 
mid-1990s due to improvements in acute care, however the prevalence of CHD is increasing largely in 
part due to the overall aging of the population, increased prevalence of cardiovascular (CV) risk factors, 
and improved survival of patients after a CV event. Data from clinical trials has consistently proven 
the efficacy of pharmacologic interventions with aspirin, statins, and blood pressure (BP)-lowering 
agents in reducing the risk of CV events and total mortality in the ever growing pool of patients in 
secondary prevention. However, large gaps between indicated therapy and prescribed medication can 
be observed worldwide, with very low rates of use of effective therapies in LMIC countries. Adherence 
to medication is very poor in chronic patients, especially those treated with multiple pharmacologic 
agents, and has been directly correlated to a greater incidence of recurrent CV events and increase in 
direct and indirect healthcare costs. In this article, we review the global burden of CV disease, status of 
secondary prevention therapy and major barriers for treatment adherence.
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Several studies in Europe have demonstrated that due to 
stabilisation of the incidence of MI and the case-fatality decrease, 
the prevalence of CHD is increasing. Recurrent CVD events are 
common in people who have already had a MI. Various studies 
have found a recurrence rate of close to 50% for any CVD event 
[7,8] or for subsequent revascularisation [9] in the year after an 
MI, and up to 75% of patients have a recurrent event within 3 years 
[8,10] (Fig. 3). A recent report from Denmark showed increasing 
prevalence of CHD associated with a decline in mortality and 
ageing of the population. The number of prevalent cases of 
CHD in Denmark increased from 125,000 in 2000 to 150,000 
in 2009 and the number of people having survived an acute MI 
increased from 67,000 to 72,000. This study showed that about 
3% of the Danish population has CHD [11]. A recent study sought 
to characterise the incidence for first and recurrent acute MI in 
England in 2010 by means of a population based national-linked 
database study. Overall, the annual age-standardised event rate 
of all acute MI (first and recurrent) per 100,000 was 174 (95% 
CI: 173–176) in men and 73.7 (95% CI: 72.9–74.5) in women. Of 
all the events that occurred: 83% were first acute MIs and 13% 
were re-infarctions. One-third (32%) of all acute MIs were fatal, 
with about two-thirds of deaths being sudden acute MI deaths. 
Similar proportions of all events were first and recurrent acute MI 
deaths (23% and 21%, respectively) [12]. In the USA, an estimated 
300,000 have a recurrent attack [6]. In addition, 17.1% of acute MI 
were followed by a readmission within 30 days in 2009. For 1.6% 
of the index admissions the reason for readmission was a new 
MI, while for 2.0% the reason was a scheduled revascularization, 
for 2.3% it was heart failure or shock and the remaining 11.2% 
of index admissions were readmitted for other conditions and 
procedures [10].
As short-term survival in acute MI hospitalised patients 
improves, it becomes more important to understand the 
implications for longer-term prognosis, both with respect to 
survival and the risk of recurrence [13]. Factors associated with 
higher risk of recurrence include: older age, socioeconomic 
status, no revascularization procedures, presence of co-
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Fig. 1. CV death rates per 100,000 population (age-standardized rates), the World Health Organization 2012 [3].
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Fig. 2. Ischaemic heart disease mortality rates 2012 (or nearest year) from the 
Eurostat Statistics Database [60].
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morbidities, and lack of adherence to secondary prevention 
medication [12]. Both clinical care and secondary prevention are 
important in improving the long-term outcome of hospitalized 
patients with acute MI.
Current status of secondary prevention, accessibility and 
adherence to cardiovascular drugs
According to a WHO report, effective reduction of CV mortality 
should be based on three key points: surveillance (mapping 
and monitoring the epidemic of CVDs), prevention (reducing 
exposure to risk factors) and management (equitable health care 
for people with CVD) [14] (Fig. 4).
Overwhelming data from clinical trials show that pharma-
cologic interventions with aspirin, statins, and BP (BP)-lowering 
agents considerably reduce the risk of vascular events and total 
mortality [15–17]. Current European Cardiovascular Prevention 
Guidelines in patients with established coronary artery disease 
recommend the use of antiplatelet therapy, lipid-lowering agents 
when low-density lipoprotein (LDL) cholesterol ≥2.5 mmol/L, 
a beta-blocker, and additional BP-lowering agents in the case 
of a systolic BP ≥140 mm Hg, unless contraindicated [18,19]. 
The American Heart Association and the American College of 
Cardiology Foundation (AHA/ACCF) Guidelines promote the 
standard use of cholesterol-and BP-lowering agents, regardless 
of the initial levels of LDL cholesterol or BP in patients with 
established vascular disease [20,21].
In clinical practice, a substantial proportion of CHD patients 
should be treated with aspirin, a statin, and BP-lowering agents 
as a result of tailored and/or step-up therapy. However, large 
gaps between indicated therapy and prescribed medication can 
be observed worldwide, with very low rates of use of effective 
therapies in LMICs countries [22,23]. In the secondary prevention 
setting in high-income countries, around 60% of patients 
are prescribed anti-platelet therapy, 50% beta-blockers, 40% 
angiotensin converting enzyme inhibitor (ACEI) or angiotensin-
receptor blocker (ARB) and almost 70% statins [23]. An analysis 
of data from the Antiplatelet Treatment Observational Registry 
(APTOR) in 14 European countries showed that only 43% of 
patients who had an acute coronary syndrome (ACS) event 
between 2007-2009 were receiving optimal secondary prevention 
(defined as use of aspirin and clopidogrel as well as three or 
more of the following post-discharge medications: statins, 
beta-blockers, ARB/ACEI, exercise or diet) at baseline and 1-year 
post-discharge. There was considerable variation by country in 
prescription of optimal therapy with highest rates reported for 
Austria/Hungary and lowest rates for the Czech Republic [24] 
(Fig. 5). The results of a prospective epidemiological registry 
conducted in Europe showed that the overall use of combination 
therapy with aspirin, statin, and ≥1 BP-lowering agent increased 
substantially from 9% in 1996 to 66% in 2009. Except for CHD, 
the trend to use combination therapy addressed to different risk 
factors increases very slowly and that means that there are still 
a high proportion of high risk patients not achieving a complete 
protection [25]. In the USA, Muntner et al. estimated that among 
patients with a history of CV disease, only 44.5% received aspirin, 
87.8% received antihypertensive medication, and 64.6% received 
statins [26]. The WHO study on Prevention of Recurrences of 
Myocardial Infarction and StrokE (WHO-PREMISE) study found 
that in some LMICs fewer than 40% of acute MI patients received 
ACEIs, and only 20% received statins [27]. The Prospective Urban 
Rural Epidemiological (PURE) study of individuals from rural and 
urban communities in countries at various stages of economic 
development aged 35–70 years confirmed that adherence 
with drugs for secondary prevention in patients with CVD was 
generally low and worst in the low income countries; with over 
80% receiving none of the effective drug treatments in South Asia 
[23].
Another fact that might affect the therapy of patients with 
CVD is the accessibility to medication, which is highly different 
among the different regions and countries of the world. In 
the EU, although there are differences between countries in 
relationship to healthcare systems the availability of drugs 
is very high compared to the LMICs. Cameron et al. assessed 
the availability of a basket of 15 medicines in the public and 
private sectors of 36 LMICs. Overall, generic medicines were 
not adequately available in both the public and private sectors 
(median availability of 38% and 64%, respectively) [29]. An 
analysis performed by Commonwealth Fund survey revealed 
that in the USA, particularly the relatively young and healthy, 
are more likely to use prescription drugs than are the residents 
of Australia, Canada, Germany, the Netherlands, New Zealand, 
and the UK, but they also experience more financial barriers 
in accessing medications and spend more out-of-pocket for 
prescriptions. In the USA, there are also larger income-related 
inequities in pharmaceutical use [28].
Low adherence: prevalence, causes and burden of disease of 
non-adherence
On the other hand, adherence to prescribed medication – the 
extent to which patients take their medications as prescribed – 
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Fig. 3. Risk of a second acute myocardial infarction (AMI) over 7 years among 
30-day survivors of first acute MI by gender, 2004 to 2010, England [13].
 
Fig. 4. Vision on how to address cardiovascular disease (CVD): World Health 
Organization 2011 [1].
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is generally poor for all diseases but especially poor for chronic 
conditions requiring long-term drug treatment such as CVD 
[29,30]. A systematic review of studies in adherence among 
patients with CVD showed that overall adherence was 57% over 
a median of 24 months [31]. In a systematic review and meta-
analysis of 44 unique prospective studies (cohort, nested case–
control, or clinical trial) comprising 1,978,919 non-overlapping 
participants at high CV risk, showed that 60% of included 
participants had good adherence (adherence ≥80%) to CV 
medications [32].
WHO has categorized potential barriers for medication 
non-adherence into five groups, including patient, condition, 
treatment, socioeconomic, and health system related factors 
[33,34]. The most common barriers for medication non-
adherence have been the focus of numerous investigations of 
adherence [35,36]. The cross-sectional Phase 1 of the FOCUS 
(Fixed-Dose Combination Drug for Secondary Cardiovascular 
Prevention) study showed that the risk of being non-adherent 
was associated with younger age, depression, being on a complex 
medication regimen, poorer health insurance coverage, and a 
lower level of social support [37]. The concern about medication 
side effects and patient’s lack of confidence in the benefit of 
treatment all play a role in the lack of adherence. Poor provider-
patient relationship and difficulties accessing physicians or 
pharmacies are, among other, relevant socioeconomic factors 
[38]. Choudhry et al. conducted a retrospective study in a 
cohort of lower income post-MI retired patients in the USA. 
Results showed that only 38.6% of patients receiving a statin 
after discharge were fully adherent [39]. Finally, Akincigil et al. 
examined the duration of CV treatment within 24 months after 
a MI. 7% of patients receiving ACEI prescription discontinued 
treatment within 1 month, 22% at 6 months, 32% at 1 year and 
50% at 2 years [40]. Finally, suboptimal medication adherence 
is associated with racial/ethnic minority groups. Ens et al. 
literature review examining factors contributing non-adherence 
to CV medications in South Asian´s (India and Pakistan) showed 
that medication side-effects, cost, forgetfulness and higher 
frequency of dosing contributed to non-adherence. South Asian 
immigrants also faced language barriers, which contributed to 
non-adherence [41].
Many studies have evaluated the effect of adherence with 
prescribed medications on outcomes in patients with existing 
CVD who need secondary prevention therapy [42–44]. These 
studies show that good adherence (generally defined as >80% 
adherence) to the combined therapy with aspirin, ACEI, beta-
blockers and statins is associated with improved outcomes 
(reduction in CV events, all-cause mortality or CVD mortality, 
and reduced medical or pharmacy costs) [42–44]. So, in the 
previously cited systematic review and meta-analysis conducted 
by Chowduhry et al. of participants at high CV risk (≥18 years 
old), risk estimates of CVD (defined as any fatal or non-fatal 
CHD, stroke or sudden cardiac death) and/or all-cause mortality 
(defined as mortality from any cause) outcomes were reported. 
Overall, 60% (95% CI: 52–68%) of included participants had good 
adherence (adherence ≥80%) to CV medications. The relative 
risk reduction (RRR) of any CV disease in the adherent patients 
was of a 20% when compared to patients with poor adherence 
(RR 0.80 [95% CI: 0.77–0.84]) Corresponding RRR in all-cause 
mortality was of a 38% in good vs. poor adherers (RR 0.62 
[95% CI: 0.57–0.67]. These associations remained consistent 
across subgroups representing different study characteristics. 
According to these results, a considerable proportion of all CVD 
events (approximately a 9% in Europe) could be attributed to 
poor adherence to vascular medications alone [32]. In the USA, 
Newby et al analyzed the use of evidence based therapies during 
the period from 1995 to 2002 for patients with documented CHD 
in the Duke Databank for Cardiovascular Disease. They showed 
that consistent use of CV medication in patients with CHD was 
asso ciated with statistically significant lower adjusted mortality 
[45].
The burden of acute coronary syndromes (ACS) to healthcare 
services in five European countries (UK, France, Germany, Italy 
and Spain) was determined including medications prescribed, 
intervention rates and hospital utilisation as well as health 
outcomes during the first year following a diagnosis of ACS. All 
costs were reported in 2004 Euros. Overall, the major contributors 
to total costs were hospital stay and revascularisation procedures. 
The total cost of ACS was estimated to be €1.9 billion in the UK, 
€1.3 billion in France, €3.3 billion in Germany, €3.1 billion in 
Italy and €1.0 billion in Spain. The cost per ACS patient ranged 
from €7,009 in the UK to €12,086 in Italy [46]. The results of a 
systematic review studying the impact of medication adherence 
on CHD costs and outcomes found that the annual cost of 
treating an adherent compared to a non-adherent patient was 
significantly different ($4,040 versus $4,940 respectively, p<0.01) 
[47]. A systematic review concluded that the overall costs of care 
are lower in patients who are adherent to secondary prevention, 
although medication costs are higher in adherent patients than 
those who do not take their prescribed medications [47]. Finally, 
out-of-pocket payments for the treatment of CV diseases lead to 
significant costs for households in LMICs. Up to 71% of patients 
who had an acute stroke were found to face catastrophic health 
expenditure in China, and 37% of them fell below the poverty 
line (1 USD per day) after paying for healthcare bills [48]. 
This evidence shows the potential of strategies that increase 
adherence to cut direct healthcare costs.
Strategies to improve adherence to medications: 
an integrated approach
Different disease specific, patient, provider and health 
system barriers have already been identified as key players to 
be addressed in order to increase adherence across populations 
[38,49]. Measures to enhance adherence to help maximize the 
potentials of effective cardiac therapies in the clinical setting 
are urgently required. This is reflected in the ESC Cardiovascular 
prevention Guidelines, where adherence assessment in 
secondary prevention is a Class 1A recommendation stating 
that physicians must assess adherence to medication, and 
identify reasons for non-adherence in order to tailor further 
interventions to fulfill the individual needs of the patient or 
person at risk [19].
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Fig. 5. Use of optimal therapy by country cluster after hospital discharge [24].
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Patient-targeted strategies
Strategies to address therapy-related barriers to medication 
adherence in patients with CV disease have primarily focused 
on reducing the complexity of the prescribed medical regimen. 
Polypharmacy is a potentially modifiable and important 
component of adherence to medical therapy for patients with 
chronic conditions. Different ad-hoc tools such as electronic 
medication aid caps have been developed to be delivered 
directly to the patient to enhance use of CV medications as 
prescribed. In addition, technology based strategies such as 
cutting edge-technology in pill bottles which communicate with 
a health-coach [50] are being studied at this time. As a matter 
of fact, the Randomized Evaluation to Measure Improvements 
in Non-adherence from Low-Cost Devices (REMIND) trial is 
currently evaluating the impact on medication adherence of 
three different pill-box devices [51]. Data showing the efficiency 
of these approaches is still lacking. Another novel strategy that 
attempts to address the adherence issue is the use of a CV polypill 
as evidence suggests that reducing dosage demands is the most 
effective single approach to enhancing medication adherence 
[19]. Including the key medications necessary to reduce CV 
risk into a single, once daily dose pill improves treatment 
adherence, and could reduce CV events, hospitalizations and 
therefore lower costs [52,53]. The Heart Outcomes Prevention 
Evaluation (HOPE-4) trial [34] and the Secondary prevention of 
CardiovascUlaR disease in the Elderly (SECURE) trial are large 
CV outcomes-based randomized controlled trials testing the 
polypill concept.
Provider-targeted strategies
Strategies aimed at improving patient´s knowledge towards 
CV disease and use of medication as prescribed have increasingly 
focused on the role of highly labor intensive multidisciplinary 
care teams. These programs involve, between others, strategies 
such as individual counseling, medication education, pharmacy 
post-discharge programs and visiting nurse or nurse-practitioner 
based services. Berben et al. evaluated which strategies CV nurses 
and allied health professional utilize to enhance medication 
adherence. Results showed that educational interventions were 
the most frequently used tools. As a matter of fact, participants 
reported using a higher proportion of educational/cognitive 
interventions (36%) than counseling/behavioral (32%) or psycho-
logical/effective interventions (23%). Reading materials about 
CV care was the most used adherence-enhancing specific 
intervention, with 66% of respondents using it frequently. Only 
the half of the participants (48%) reported that they frequently 
trained patients on how to properly take their medications as 
prescribed during their inpatient recovery [54]. Nieuwkerk et al. 
examined the effect of nurse-led counseling program regarding 
CV risk on adherence to statins. Patients taking statins for either 
primary or secondary prevention of CV disease were randomized 
to routine care or to the intervention arm. The intervention 
consisted of nurse-led individualized counseling regarding CV 
risk and subsequent regular visits to assess the degree of control 
of dyslipidemia and other CV risk factors. At the completion of 
the trial, self-reported adherence to statins was significantly 
higher in the intervention arm as compared to those who 
received routine care (100% vs. 95%; p<0.05) [55]. The addition 
of a clinical pharmacist to monitor patients with CVD can lead 
to an improvement in CVD patients in many areas, including 
patient improvement of adherence medications and preventing 
potential drug-related problems. Hohmann et al evaluated the 
adherence to hospital discharge medication in patients with 
ischemic stroke before and after implementing a program 
provided by a clinical pharmacist. In the intervention group, the 
clinical pharmacist listed the medication at discharge and gave 
detailed information for all medication changes during hospital 
stay. Significant differences between the control group and 
intervention group were established with regard to adherence to 
both antithrombotic medications (83.8% control group vs. 91.9% 
intervention group, p=0.033) and to statin therapy (69.8% control 
group vs. 87.7% intervention group; p<0.001) [56]. None of these 
studies mentioned before reported economic outcomes.
Health system-targeted strategies
Medication non-adherence is increasingly recognized to 
be associated with socioeconomic adversity. Factors such as 
poverty and in particular food insufficiency and hunger [57], 
and unstable housing [58] have been associated with medication 
non-adherence in other chronic conditions such as human 
immunodeficiency virus and acquired immune deficiency 
syndrome (HIV/AIDS). In relation to CVD, low socioeconomic 
status has been found to be associated with low adherence in a 
number of different environments. Pharmacy benefit programs 
have a direct influence on adherence to medicines. Higher copays 
and restricted benefits lead to a reduction in use of medicines 
as prescribed. The Rand study performed in the USA found 
that doubling copays for commonly used drug classes reduced 
adherence by 25% to 45% [57].
Strategies may be more effective if they: 1) are designed 
for specific groups; 2) take into account behavioral patterns; 
and 3) are based on evidence-based specific tools or programs. 
Multifaced strategies simultaneously directed at patients, 
physicians/practices, and healthcare or social systems targeting 
physician prescribing behavior as well as interventions to 
reduce social, financial and treatment-related barriers to enable 
patients to adhere to prescribed therapy have been found to be 
most effective in low income groups. Moreover, complex multi-
factorial strategies, addressing different barriers have been 
mostly assessed without previous evaluation of their individual 
components [59]. Individual interventions such as simplifying 
dosage regimens and fixed combination pills appear to be the 
most effective tool. The European Guidelines on CVD prevention 
recommend all the physicians to reduce dosage demands of their 
patients to the lowest feasible level and additionally, to provide 
clear advice regarding the benefits and possible adverse effects 
of the medication as well as of the duration and timing of dosing. 
It is recommended to consider patients’ habits and preferences 
and to ask patients in a non-judgmental way how the medication 
works for them, discussing possible reasons for non-adherence 
(e.g. side effects, worries). After the assessment of adherence it 
is important to implement repetitive monitoring and feedback, 
offering multisession or combined behavioral interventions 
in the case of persistent non-adherence through physicians 
assistants and/or trained nurses [19].
Conclusion
It is clear that the current CVD pandemic calls for a revision 
of the way we implement healthcare worldwide, as well as new 
simple, efficacious and efficient strategies to contain the growth 
of the disease worldwide.
The scenario in LMIC is especially worrisome, as many regions 
suffer what has been called the double burden of disease (that 
is, developing regions where communicable diseases are highly 
prevalent are also suffering the health toll from chronic, non-
communicable diseases). In high income countries the higher 
survival rate after a CV event, the aging of the population and 
the increase in prevalence of CV risk factors has increased the 
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cost of treating CVD to a degree that will not be sustainable even 
in the wealthiest economies. Even in high income European 
countries where medication accessibility is guaranteed the 
efficacy of proven treatments is severely hampered due to 
poor adherence rates to pharmacologic therapy (consistently 
shown to be about 45–60% in secondary prevention). Hence, 
interventions toward improving adherence rates could have a far 
greater impact on public health than any individual treatment. 
Barriers to medication adherence might be surpassed through 
programs delivered through the healthcare system, through 
multidisciplinary care teams or directly by the patient by 
reducing the dosage demands which could include the intake 
of CV polypills. Hence, from a public health perspective, it is of 
highest importance implement existing and innovative strategies 
to achieve adequate adherence to secondary CV prevention 
medication in order to ensure efficacy of treatment.
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